Pfizer Buys Option For Vivet In Latest Gene Therapy Tie-Up
The big pharma has acquired a 15% equity stake in the privately-held gene therapy developer and an option to purchase all outstanding shares.
The big pharma has acquired a 15% equity stake in the privately-held gene therapy developer and an option to purchase all outstanding shares.